DE69131021D1 - Angiotensin-ii-rezeptor blockierende zusammensetzungen - Google Patents

Angiotensin-ii-rezeptor blockierende zusammensetzungen

Info

Publication number
DE69131021D1
DE69131021D1 DE69131021T DE69131021T DE69131021D1 DE 69131021 D1 DE69131021 D1 DE 69131021D1 DE 69131021 T DE69131021 T DE 69131021T DE 69131021 T DE69131021 T DE 69131021T DE 69131021 D1 DE69131021 D1 DE 69131021D1
Authority
DE
Germany
Prior art keywords
angiotensin
receptor blocking
blocking compositions
blocker
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131021T
Other languages
English (en)
Other versions
DE69131021T2 (de
DE10399008I1 (de
Inventor
Joseph Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69131021D1 publication Critical patent/DE69131021D1/de
Publication of DE69131021T2 publication Critical patent/DE69131021T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69131021T 1990-12-14 1991-12-13 Angiotensin-ii-rezeptor blockierende zusammensetzungen Expired - Lifetime DE69131021T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62880790A 1990-12-14 1990-12-14
PCT/US1991/009362 WO1992010097A1 (en) 1990-12-14 1991-12-13 Angiotensin ii receptor blocking compositions

Publications (2)

Publication Number Publication Date
DE69131021D1 true DE69131021D1 (de) 1999-04-22
DE69131021T2 DE69131021T2 (de) 1999-08-12

Family

ID=24520386

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1991631021 Pending DE10399008I1 (de) 1990-12-14 1991-12-13 Angiotensin-II-Rezeptor blockierende Zusammensetzungen
DE69131021T Expired - Lifetime DE69131021T2 (de) 1990-12-14 1991-12-13 Angiotensin-ii-rezeptor blockierende zusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1991631021 Pending DE10399008I1 (de) 1990-12-14 1991-12-13 Angiotensin-II-Rezeptor blockierende Zusammensetzungen

Country Status (14)

Country Link
EP (1) EP0565634B1 (de)
JP (1) JP3398379B2 (de)
KR (1) KR100222252B1 (de)
AT (1) ATE177634T1 (de)
AU (1) AU656551B2 (de)
CA (1) CA2098176C (de)
DE (2) DE10399008I1 (de)
DK (1) DK0565634T3 (de)
ES (1) ES2130170T3 (de)
GR (1) GR3030293T3 (de)
HK (1) HK1012209A1 (de)
LU (1) LU91234I2 (de)
NL (1) NL300115I2 (de)
WO (1) WO1992010097A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
CN1215338A (zh) * 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
EP0910375B1 (de) * 1996-06-24 2002-05-02 Merck & Co., Inc. Zusammensetzung auf basis von enalapril und losartan
NZ502644A (en) * 1997-08-06 2002-03-01 Smithkline Beecham Corp Eprosartan arginyl charge-neutralization-complex useful for treating diseases where blockade of the angiotensin II receptor is indicated
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
EP3045174A1 (de) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medikament zur vorbeugung und behandlung von arteriosklerose und bluthochdruck
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
EP1722785A4 (de) * 2004-03-08 2009-07-08 Wyeth Corp Ionenkanal-modulatoren
BRPI0508880A (pt) * 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
US20100143470A1 (en) * 2006-10-30 2010-06-10 Hanall Pharmaceutical Company, Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2275093A2 (de) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmazeutische formulierung
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112014027618A2 (pt) 2012-05-07 2017-06-27 Bayer Pharma AG processo para a fabricação de uma forma de dosagem farmacêutica compreendendo nifedipina e candesartan cilexetil
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0565634B1 (de) 1999-03-17
DE69131021T2 (de) 1999-08-12
EP0565634A1 (de) 1993-10-20
AU9178291A (en) 1992-07-08
AU656551B2 (en) 1995-02-09
LU91234I2 (fr) 2006-06-12
DE10399008I1 (de) 2006-06-08
WO1992010097A1 (en) 1992-06-25
NL300115I1 (nl) 2003-05-01
CA2098176C (en) 2006-12-12
ES2130170T3 (es) 1999-07-01
KR100222252B1 (ko) 1999-10-01
ATE177634T1 (de) 1999-04-15
JPH06503834A (ja) 1994-04-28
EP0565634A4 (en) 1996-04-17
GR3030293T3 (en) 1999-09-30
NL300115I2 (nl) 2003-09-01
DK0565634T3 (da) 1999-09-27
CA2098176A1 (en) 1992-06-14
HK1012209A1 (en) 1999-07-30
KR930702895A (ko) 1993-11-29
JP3398379B2 (ja) 2003-04-21

Similar Documents

Publication Publication Date Title
ATE177634T1 (de) Angiotensin-ii-rezeptor blockierende zusammensetzungen
TR199900591T2 (xx) Geri ak�� �nleyicileri.
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
MX9705674A (es) Antagonistas hexahidrobenz(e)isoindol alfa-1 adrenergicos, triciclos substituidos.
IL122242A0 (en) Combination of angiotensin II receptor and epoxy-steroidal aldosterone receptor antagonist
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
EP1009435A4 (de) Verfahren zur vorbeugung von hiv-jnfektion von cd4?+zellen
DK0805812T3 (da) Bicyklisk substitueret hexahydrobenz[e]isoindol som alfa-1-adrenerge antagonister
IL70882A0 (en) Certain benzazocinone and benzazoninone derivatives
MX9202243A (es) Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.
DK0859784T3 (da) Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
EP0726072A3 (de) Zusammenstellung zur Behandlung von Hypertonie und congestiven Herzensagens, die ein Angiotensin-II-Antagonist und ein Endopeptidase Inhibitor enthält
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
EP1335747A4 (de) Zusammensetzung einer natriumkanal-blockierenden verbindung
AU3498795A (en) Method of blocking the sec receptor
ES2175437T3 (es) Composicion de enalapril y losartan.
ATA156496A (de) Pharmazeutische zusammensetzung
HU9600764D0 (en) Use of a cgrp antagonist for treating lichens and pruritus, and compositions containing this compound
NO992661L (no) Benzopyranopyrrol og benzopyranopyridin <alfa>-1 adrenerge forbindelser
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
EA199800889A1 (ru) Способ предупреждения и/или лечения сердечной недостаточности и дисфункции желудочков антагонистами эндотелина, фармацевтическая композиция
AR011730A1 (es) UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
GR3030353T3 (en) Composite cement
EA199800533A1 (ru) Композиция для лечения боли

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312

V457 Spc granted

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312